Advertisement

Infection

, Volume 39, Issue 6, pp 515–518 | Cite as

Outcomes in patients infected with carbapenem-resistant Acinetobacter baumannii and treated with tigecycline alone or in combination therapy

  • R. Guner
  • I. Hasanoglu
  • S. Keske
  • A. K. Kalem
  • M. A. Tasyaran
Clinical and Epidemiological Study

Abstract

Purpose

Acinetobacter baumannii is a non-fermenting aerobic gram-negative bacteria and one of the important nosocomial pathogens, especially in intensive care units (ICUs). In recent years, multidrug-resistant (MDR) isolates have been an emerging problem, with limited therapeutic options. Tigecycline is a novel antimicrobial, with its in vitro activity against most gram-positive and gram-negative pathogens.

Methods

This is a retrospective study that was conducted in a tertiary care hospital with 550 beds in Ankara, Turkey, from January 2009 to July 2010. Thirty-three patients who had carbapenem-resistant Acinetobacter spp. infections and received tigecycline alone or in combination with other antibiotics for at least 3 days were included.

Results

The median age of the patients was 62 (18–87) years. All of the patients were diagnosed and treated in the ICU. Clinical responses were observed in 23 patients (69.7%). Ten patients (30%) had clinical failure. There was no significant difference between ventilator-associated pneumonia (VAP) and bloodstream infection (BSI) in terms of clinical or microbiological outcome (p > 0.05). The microbiological response rate was 50%. Superinfection was detected in 13 patients (43.3%) and Pseudomonas aeruginosa was the most frequently isolated pathogen. The 30-day overall mortality rate and attributable mortality rates were 57.6 and 24.2%, respectively. The attributable mortality rate was higher in the group in which microbiological eradication was not provided.

Conclusions

Although it is approved by the Food and Drug Administration (FDA) for the treatment of complicated intra-abdominal infections, complicated skin and soft tissue infections, and community-acquired bacterial pneumonia, emerged resistance of Acinetobacter spp. and limited therapeutic options left physicians no choice but to use tigecycline for off-label indications.

Keywords

Tigecycline Acinetobacter baumannii Carbapenem-resistant Carbapenem-resistant Acinetobacter baumannii 

Notes

Conflict of interest

None.

References

  1. 1.
    Gordon NC, Wareham DW. Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance. Int J Antimicrob Agents. 2010;35:219–26.PubMedCrossRefGoogle Scholar
  2. 2.
    Ricciardi R, Ricciardi AM, Danzi G. In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii clinical isolates. Infez Med. 2009;17:236–9.PubMedGoogle Scholar
  3. 3.
    Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J, Cosgrove SE, Anderson A, Carnell J, Jernigan DB, Kleinbaum DG, Perl TM, Standiford HC, Srinivasan A. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis. 2007;13:97–103.PubMedCrossRefGoogle Scholar
  4. 4.
    Wareham DW, Bean DC, Khanna P, Hennessy EM, Krahe D, Ely A, Millar M. Bloodstream infection due to Acinetobacter spp.: epidemiology, risk factors and impact of multi-drug resistance. Eur J Clin Microbiol Infect Dis. 2008;27:607–12.PubMedCrossRefGoogle Scholar
  5. 5.
    Pankey GA. Tigecycline. J Antimicrob Chemother. 2005;56:470–80.PubMedCrossRefGoogle Scholar
  6. 6.
    TYGACIL product information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021821s021lbl.pdf. Accessed 16 July 2010.
  7. 7.
    Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16:128–40.PubMedCrossRefGoogle Scholar
  8. 8.
    Kollef MH. Diagnosis of ventilator-associated pneumonia. N Engl J Med. 2006;355:2691–3.PubMedCrossRefGoogle Scholar
  9. 9.
    Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG. CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol. 1992;13:606–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Gordon NC, Wareham DW. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother. 2009;63:775–80.PubMedCrossRefGoogle Scholar
  11. 11.
    Poulakou G, Kontopidou FV, Paramythiotou E, Kompoti M, Katsiari M, Mainas E, Nicolaou C, Yphantis D, Antoniadou A, Trikka-Graphakos E, Roussou Z, Clouva P, Maguina N, Kanellakopoulou K, Armaganidis A, Giamarellou H. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. J Infect. 2009;58:273–84.PubMedCrossRefGoogle Scholar
  12. 12.
    Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. CLSI document M100-S18. Wayne, PA: CLSI; 2008.Google Scholar
  13. 13.
    Jones RN, Ferraro MJ, Reller LB, Schreckenberger PC, Swenson JM, Sader HS. Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J Clin Microbiol. 2007;45:227–30.PubMedCrossRefGoogle Scholar
  14. 14.
    García-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J, Jiménez-Jiménez FJ, Monterrubio-Villar J, Gili-Miner M. Mortality and the increase in length of stay attributable to the acquisition of Acinetobacter in critically ill patients. Crit Care Med. 1999;27:1794–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Metan G, Alp E, Yildiz O, Percin D, Aygen B, Sumerkan B. Clinical experience with tigecycline in the treatment of carbapenem-resistant Acinetobacter infections. J Chemother. 2010;22:110–4.PubMedGoogle Scholar
  16. 16.
    Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak T, Dukart G, Cooper A, Dartois N, Gandjini H, Orrico R, Ellis-Grosse E; 309 Study Group. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother. 2008;62:i29–40.PubMedCrossRefGoogle Scholar
  17. 17.
    García-Cabrera E, Jiménez-Mejías ME, Gil Navarro MV, Gómez-Gómez MJ, Ortiz-Leyba C, Cordero E, Pachón J; Hospitale Universitarios Virgen del Rocío. Superinfection during treatment of nosocomial infections with tigecycline. Eur J Clin Microbiol Infect Dis. 2010;29:867–71.PubMedCrossRefGoogle Scholar
  18. 18.
    Kwon KT, Oh WS, Song JH, Chang HH, Jung SI, Kim SW, Ryu SY, Heo ST, Jung DS, Rhee JY, Shin SY, Ko KS, Peck KR, Lee NY. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother. 2007;59:525–30.PubMedCrossRefGoogle Scholar
  19. 19.
    Chen HP, Chen TL, Lai CH, Fung CP, Wong WW, Yu KW, Liu CY. Predictors of mortality in Acinetobacter baumannii bacteraemia. J Microbiol Immunol Infect. 2005;38:127–36.PubMedGoogle Scholar
  20. 20.
    Falagas ME, Kasiakou SK, Rafailidis PI, Zouglakis G, Morfou P. Comparison of mortality of patients with Acinetobacter baumannii bacteraemia receiving appropriate and inappropriate empirical therapy. J Antimicrob Chemother. 2006;57:1251–4.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • R. Guner
    • 1
  • I. Hasanoglu
    • 1
  • S. Keske
    • 1
  • A. K. Kalem
    • 1
  • M. A. Tasyaran
    • 1
  1. 1.Ataturk Education and Research HospitalAnkaraTurkey

Personalised recommendations